CMO, biotech, protein manufacturing, microbial fermentation, mammalian, cell banking, contract manufacturing, biopharmaceuticals, cGMP, GMP, biopharmaceutical companies.#Biopharmaceutical #companies

Posted On Mar 19 2018 by

Biotech: Biologics and cell therapy products Latest News COF Navarra 2017 Award 3P Biopharmaceuticals received last Saturday 25 November the [ ] Premio COFNavarra 2017 3P Biopharmaceuticals recibió el pasado sábado 25 de [ ] Innovation


EY news – Biopharmaceutical M – A expected to soar in 2017 as pricing pressures dim global revenue outlook – EY – United States, biopharmaceutical companies.#Biopharmaceutical #companies

Posted On Mar 18 2018 by

Biopharmaceutical M A value exceeded US$200b in 2016 Payer growth gap quickly becoming a reality for many in sector Big pharma enters 2017 with distinct firepower advantage and need to deal The biopharmaceutical industry s desire for inorganic growth is expected to intensify an already heated mergers and acquisitions (M A) environment in 2017. This is according to the EY M A Outlook and Firepower Report 2017 that was launched today. With new regulatory and tax environments expected following the changing geopolitical landscape, most notably in the post-election US, expectations are that the industry may roar past the US$200b in …


Chinese American Biopharmaceutical Society – Chinese American Biopharmaceutical Society CABS, biopharmaceutical companies.#Biopharmaceutical #companies

Posted On Mar 18 2018 by

CABS is the organizer of the BioPacific Conference , a highly anticipated annual life sciences event attended by hundreds of industry experts, employers, entrepreneurs, venture capitalists, academics and professionals. CABS is a non-profit organization for life sciences trusted by our professional members. Join the community! UPCOMING EVENTS RECENT EVENTS December 2, 2017 @ 1:00 pm December 2, 2017 @ 10:00 am August 1, 2017 @ 10:00 am May 20, 2017 @ 2:30 pm November 6, 2017 @ 12:00 am October 28, 2017 @ 3:00 pm October 22, 2017 @ 4:00 pm October 17, 2017 @ 1:00 am October 14, 2017 …


EY news – Biopharmaceutical M – A expected to soar in 2017 as pricing pressures dim global revenue outlook – EY – United States, biopharmaceutical companies.#Biopharmaceutical #companies

Posted On Jan 31 2018 by

Biopharmaceutical M A value exceeded US$200b in 2016 Payer growth gap quickly becoming a reality for many in sector Big pharma enters 2017 with distinct firepower advantage and need to deal The biopharmaceutical industry s desire for inorganic growth is expected to intensify an already heated mergers and acquisitions (M A) environment in 2017. This is according to the EY M A Outlook and Firepower Report 2017 that was launched today. With new regulatory and tax environments expected following the changing geopolitical landscape, most notably in the post-election US, expectations are that the industry may roar past the US$200b in …


EY news – Biopharmaceutical M – A expected to soar in 2017 as pricing pressures dim global revenue outlook – EY – United States, biopharmaceutical companies.#Biopharmaceutical #companies

Posted On Jan 31 2018 by

Biopharmaceutical M A value exceeded US$200b in 2016 Payer growth gap quickly becoming a reality for many in sector Big pharma enters 2017 with distinct firepower advantage and need to deal The biopharmaceutical industry s desire for inorganic growth is expected to intensify an already heated mergers and acquisitions (M A) environment in 2017. This is according to the EY M A Outlook and Firepower Report 2017 that was launched today. With new regulatory and tax environments expected following the changing geopolitical landscape, most notably in the post-election US, expectations are that the industry may roar past the US$200b in …


The Top 10 Biopharmaceutical Companies – Contract Pharma #pharma #recruitment #agencies

Posted On Nov 20 2017 by

#bio pharmaceutical companies # Related Features The Top Biophama list is stable this time around; the only change was between CSL and Genzyme, and that was mainly due to the dramatic appreciation of CSL s reporting currency, the Australian dollar. Scarily, the cumulative revenues of our Top 10 Biopharmas grew a mere 3% in 2010, compared to 4%, 14% and 16% in 2009, 2008 and 2007. That s the wrong end of the curve. Genzyme will likely show up on next year s list, depending on how Sanofi manages its financial reporting once their acquisition is closed. It s a …


AstraZeneca – Research-Based BioPharmaceutical Company #akela #pharma #inc

Posted On Aug 16 2017 by

#drug research companies # AstraZeneca live at ERS 2016 Meet Chris Rhodes, a renowned leader in the field of diabetes and obesity research I grew up in an artistic musical family, which instilled in me very early on the essence of creativity. Science requires original thinking, and cultivating and using that creativity is fundamental to innovation and momentous discovery . AstraZeneca’s ambitions for personalised healthcare go far beyond treating cancer At AstraZeneca, personalised healthcare is about matching medicines to the patients most likely to benefit from them. The approach involves a detailed understanding of the biology of a disease, identifying …


2010 Top 10 Biopharmaceutical Companies Report – Contract Pharma #pharma #stocks

Posted On Aug 12 2017 by

#bio pharmaceutical companies # Related Features Our rules for inclusion on the Top 10 Biopharma list are as follows: you re a biopharma company if more than half of your drug revenues not royalties come from large-molecule drugs and vaccines. It s arbitrary, but it s worked pretty well for the past decade. This year, it means that Roche/Genentech has become the world s #1 biopharma, marking the first change at the top in 10 years. The rest of this year s list is consistent with the previous year s ranks, which is both a sign of the stability among …


2010 Top 10 Biopharmaceutical Companies Report – Contract Pharma #pharma #supply

Posted On Aug 5 2017 by

#bio pharmaceutical companies # Related Features Our rules for inclusion on the Top 10 Biopharma list are as follows: you re a biopharma company if more than half of your drug revenues not royalties come from large-molecule drugs and vaccines. It s arbitrary, but it s worked pretty well for the past decade. This year, it means that Roche/Genentech has become the world s #1 biopharma, marking the first change at the top in 10 years. The rest of this year s list is consistent with the previous year s ranks, which is both a sign of the stability among …


The Top 10 Biopharmaceutical Companies – Contract Pharma #phrma

Posted On Jul 28 2017 by

#bio pharmaceutical companies # Related Features The Top Biophama list is stable this time around; the only change was between CSL and Genzyme, and that was mainly due to the dramatic appreciation of CSL s reporting currency, the Australian dollar. Scarily, the cumulative revenues of our Top 10 Biopharmas grew a mere 3% in 2010, compared to 4%, 14% and 16% in 2009, 2008 and 2007. That s the wrong end of the curve. Genzyme will likely show up on next year s list, depending on how Sanofi manages its financial reporting once their acquisition is closed. It s a …